2012—2014年复旦大学附属上海市第五人民医院口服降糖药应用分析  

Analysis on Application of Oral Hypoglycemic Drugs in the Fifth People's Hospital of Shanghai Fudan University during 2012-2014

作　　者：宋锦飞[1] 孙光春[1] 

机构地区：[1]复旦大学附属上海市第五人民医院药剂科,上海200240

出　　处：《中国医院用药评价与分析》2016年第1期63-65,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的：了解复旦大学附属上海市第五人民医院（以下简称＂我院＂）门诊口服降糖药的应用现状与发展趋势,为临床合理用药提供参考。方法：采用限定日剂量、用药频度（defined daily dose system,DDDs）和限定日费用等客观指标,统计分析2012—2014年我院门诊口服降糖药用药情况。结果：3年内口服降糖药物的使用品种及销售金额逐年增长;DDDs排序前3位的药品为格列吡嗪、二甲双胍和瑞格列奈;销售金额排序前3位的药品为阿卡波糖、瑞格列奈和格列美脲;销售金额序号与DDDs排序比值在0.20~5之间。结论：格列吡嗪、二甲双胍和瑞格列奈连续3年的用量居主导地位,我院门诊口服降糖药应用基本合理。OBJECTIVE： To investigate the application status and development trend of oral hypoglycemic drugs in outpatient departments of the Fifth People＇s Hospital of Shanghai Fudan University（ hereinafter referred to as ＂our hospital＂）,and to provide reference for the rational drug use in clinic. METHODS： The subjective indicators as defined daily dose（ DDD）,defined daily dose system（ DDDs） and defined daily cost（ DDC） were adopted to statistically analyze the application situation of oral hypoglycemic in the outpatient department of our hospital during2012-2014. RESULTS： The varieties and consumption sum of oral hypoglycemic drugs increased year by year. The top3 hypoglycemic drugs ranked by DDDs were glipizide,dimethylbiguanide and repaglinide. The top 3 hypoglycemic drugs ranked by consumption sum were acarbose,repaglinide,glimepiride. The ratio of consumption sum serial number versus DDDs serial number was within 0. 20-5. CONCLUSIONS： The application amount of glipizide,dimethylbiguanide and repaglinide dominated the first place for three consecutive years,and the application of oral hypoglycemic drugs is basically rational in our hospital.

关 键 词：口服降糖药 用药频度 用药分析 

分 类 号：R977.15[医药卫生—药品]